文章：

PRMT5：前列腺癌的推定癌基因和治疗靶点

PRMT5: a putative oncogene and therapeutic target in prostate cancer

原文发布日期：2021-04-14 

英文摘要：

Protein arginine methyltransferase 5 (PRMT5) was discovered two decades ago. The first decade focused on the biochemical characterization of PRMT5 as a regulator of many cellular processes in a healthy organism. However, over the past decade, evidence has accumulated to suggest that PRMT5 may function as an oncogene in multiple cancers via both epigenetic and non-epigenetic mechanisms. In this review, we focus on recent progress made in prostate cancer, including the role of PRMT5 in the androgen receptor (AR) expression and signaling and DNA damage response, particularly DNA double-strand break repair. We also discuss how PRMT5-interacting proteins that are considered PRMT5 cofactors may cooperate with PRMT5 to regulate PRMT5 activity and target gene expression, and how PRMT5 can interact with other epigenetic regulators implicated in prostate cancer development and progression. Finally, we suggest that targeting PRMT5 may be employed to develop multiple therapeutic approaches to enhance the treatment of prostate cancer. 

摘要翻译：

蛋白精氨酸甲基转移酶5（PRMT5）于二十年前被发现。首个十年研究主要聚焦于PRMT5作为健康机体中多种细胞进程调节因子的生化特性。然而在过去十年间，越来越多的证据表明PRMT5可能通过表观遗传和非表观遗传机制在多种癌症中发挥癌基因功能。本综述重点关注前列腺癌领域的最新进展，包括PRMT5在雄激素受体（AR）表达与信号传导以及DNA损伤应答（特别是DNA双链断裂修复）中的作用。我们同时探讨了被视为PRMT5辅因子的相互作用蛋白如何协同PRMT5调控其活性和靶基因表达，并分析PRMT5如何与前列腺癌发生发展过程中涉及的其他表观调控因子相互作用。最后，我们提出靶向PRMT5可能为开发多种治疗策略以增强前列腺癌治疗效果提供新途径。

原文链接：

PRMT5: a putative oncogene and therapeutic target in prostate cancer